October 19-20, 2016

Innovation Quality Service

Sinovet (Beijing) Biotechnology Co., Ltd

Shucheng Zhang, DVM, PhD

Sinovet

• A private research-based company • Business focus: Animal biological

product development, manufacture, and marketing

• Company core value: innovation, quality, and service

Sinovet (Beijing) Biotechnology Co.,

Ltd ，

Sinovet (Jiangsu) Biopharmaceutical Co., Ltd

China Medical City ， Taizhou

Sinovet Sites

Fact of SinovetSinovet (Beijing) was established in 2010 after splitting from another

biological company (Headquarter + Marketing)Sinovet (Jiangsu) was established in 2011 in China Medical City in

Taizhou, Jiangsu ( Production + R&D + Marketing)Major business units: R&D, Production, and MarketingEmployee: 200 plus Investment Capital : US$ 30 millionsRevenue (2015) : US$ 10 millions

Board of Directors

Wu, Hua Chairman, President

Zhao, Jianzeng Director

Vice-President Marketing

Wu, Qiong Director

Vice-President HR and Finance

Wang, Wei Secretary，GM， R&D RegulatoryBusiness

Zhang, Shucheng Director

Vice-President Manufacture

and R&D

Company Structure

Board of Directors

President

Marketing R&D Center Production

Legal/ Business Finance HR

Wu, Hua President , CEO

Zhao, Jianzeng

VP, Marketing Lu, Wei

General Manager, South China

Regions

Tian, Changxiao General Manager

Key Customer Account

Chen, Lei,General Manager,

North China Regions

Shi, XinchuanGeneral Manager Bovine Products

Zhang, Shucheng VP, R&D,

Production

Su, Weiwei, General Manager, Sinovet (Jiangsu),

Production, QC, QA

Wang, WeiGeneral Manager ， R&D RA, Business,

Networking

Xia MingqiAssociate General M ， R&D Swine

Diseases

He, Yanliang Associate General M,

R&D Small Animal Diseases

Li, Zhenguang Associate General M, R&D Bovine Diseases

Wu, Qiong VP, HR,

Finance

Wu ， Yingying Associate General Manager, Finance

Xu, Jianjun Manager, Human

Resource

Sinovet Leadership Team

Milestones of Sinovet

2013

2010

2011

2012 2014 2016

2015

Sinovet (Beijing) established

Sinovet (Jiangsu) establishedHP PRRS vaccine licensed

HP-PRRS/CSF combo vaccine clinical trial

Two production lines accredited for GMP

HP PRRS-CSF combo vaccine licensed

Two more production lines accredited for GMP PRV, HP-PRRS (bioreactor), BVD licensed First product (CSF) on market

Sinovet (Jiangsu) construction completed

R&D Center Research Teams: 35+ scientists Research Focus: Animal (swine, bovine, C&A )

vaccines and diagnostic reagents/kits Key Technologies/resources

Suspension cell technology Lyophilization/Stabilizer platform Genetic engineering technology Network and collaborations Local strain access and acquisition through surveillance

program

R&D Center

R&D Center Swine

HP–PRRSLive

PRRS-CSF Combo

PRRS-CSF-PRV Combo

PRRS-PRV combo

SIV

PCV2

Bovine

BVD, Killed

BVD-IBRKilled

BVD-IBR Live

Bovine Multiple Combo

Small Animal

MEV-CDV live

Bacterial Vaccines

Rabies

Technology

Suspension cells

Adjuvant

Vaccine Processing

Business/ Regulatory

Regulatory Affairs

IP

Networking

Business and Legal

Diagnosis

Monoclonal antibodies

Diagnostic kits

Tech service support

R&D Laboratories

R&D Teams

Sinovet Pipelines

Post 2020Pre 2014 2015 2016 2017 2018 2019

HP-PRRS

/CSF

Combo

HP-PRRS (

Bioreac

tor)

CSF (

Cell)

BVD ki

lled

PRV (B

arth

a K61

)

HP-PRRS/

PRV Li

ve Co

mbo

BVD /I

BR Killed Co

mboBV

D/IBR Li

ve Co

mbo

MEV

/CPV

(Mink

) Live

Combo

CSF (

co/IF

A as Q

C tes

t ）

HP PRRS (

RB)

HP-PRRS/

CSF/

PRV Li

ve Co

mbo

PCV2 M. hyo PCV2/M. hyo combo PED/TGE combo Cattle 5-way vaccine Diagnostic kits

SIV Biva

lent k

illed

SSinovet New Product Projection

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 20110

2

4

6

8

10

12

14

16

18

20

Existing products New Products

Num

ber o

f Pro

duct

s

Innovation Example I HP-PRRS/CSF Live Combo Vaccine

Innovation Points:• First PRRS/CSF combo vaccine • Most safe vaccine HP PRRSV strain with

double gene deletions • PRRS vaccine strain without

immunosuppression and interference to other vaccines

• Innovation testing method for CSF final product

Innovation Example II Suspension Cell Technology

MDCK Cells

Marc-145 Cells

Adherence Cells Suspension Cells

Highlights:

- Serum free medium- No micro- carrier- High virus titer - Proprietary technology

Intellectual Properties

• Chinese patents• Published - 12 • Pending application - 4

• International patents • Published - 3 (filed in 15

countries )• Pending application - 1

• Trademarks• Approved - 1• Pending applications - 25

Manufacture

M

Manufacture Team

Production Capacity and Production Lines

Capacity of production facility （ 400 M）• Live viral vaccine - 200 million dose • Killed viral vaccine – 120 million dose • Killed bacterial vaccine – 80 million dose

GMP-certified production lines Live virus vaccine (Roller Bottles) Live virus vaccine (Bioreactors) Killed virus vaccine (Roller Bottles) Killed bacterial vaccine (Fermenter)

Production lines to be established (phase II) Killed virus vaccine (Bioreactors) Live bacterial vaccine

Manufacture Space and Environment 冻干系统

Bioreactors (500L)

Vaccine Mixing and Assembly Lines

Product Quality Control

• Experienced management Team

• Well-trained team for each position

• State-of-art Facility

• Strictly enforced GMP system

Manufacture/ Management

Quality Control

Quality Assurance

• Raw material• Package

materials • Antigen batches

and critical reagents

• Final product • Regular

environment monitoring

• Water system

• Manufacture process and environment

• Water and gas supply system

• Product release process

• Costumer feedback

• Documentation system

Marketing and Technical Service

Marketing and Technical ServiceOrganization

Marketing

Sales

South China

North China

Large Farms

Technical Service

Tech Service Team

Diagnostic Lab

Training and Technical Service

Major Partners and Collaborators

Institute of Veterinary Drug Control Pfizer (Zoetis) Animal Health Tiankang Animal Health China Animal Husbandry Group

Government Sponsored Researches

Name of Project Sponsors Funding Studies on diagnostic technology of cattle and sheep

MOST US$ 200K

Studies on prevention/control technology of major infectious diseases of cattle and sheep

MOST US$ 1000K

Stress effect on bovine respiratory diseases MOST US$ 200KStudies on lyophilization/stabilizer for cattle vaccines

MOST US$ 500K

Studies on animal vaccine technology MOST US$ 200KStudies on cell suspension for animal vaccine development

MOA US$ 170K

Industrialization research on CSF/PRRS combo vaccine

JPST US$ 900K

PRSSV differential diagnosis JPST US$ 40K

MOST: Ministry of Science and Technology; MOA: Ministry of Agriculture; JPST: Jiangsu Province Science and Technology Department

Research Collaborations with Universities and Research Institutes

Research Collaborations with University and Research Institutes

Collaborations with Pfizer/Zoetis

Collaborations with Animal Health Companies

Sinovet - A Leader for Future

THANK YOU

Website: www.sinovetah.com